QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:TLRY

Tilray (TLRY) Stock Price, News & Analysis

$1.74
-0.02 (-1.14%)
(As of 02/26/2024 ET)
Today's Range
$1.71
$1.78
50-Day Range
$1.76
$2.41
52-Week Range
$1.50
$3.40
Volume
13.63 million shs
Average Volume
22.69 million shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.83

Tilray MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
62.8% Upside
$2.83 Price Target
Short Interest
Healthy
15.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Tilray in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$183,210 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.23) to ($0.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.53 out of 5 stars

Consumer Staples Sector

86th out of 126 stocks

Medicinals & Botanicals Industry

4th out of 11 stocks


TLRY stock logo

About Tilray Stock (NASDAQ:TLRY)

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Nanaimo, Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

TLRY Stock Price History

TLRY Stock News Headlines

Exit Now! 3 Penny Stocks to Sell in February 2024
TLRY Mar 2024 1.000 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
TLRY Feb 2024 3.500 put
Solei Brand Launches New Cannabis Infused Cold Brew Teas
7 Millionaire-Maker Penny Stocks to Buy in February 2024
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Tilray Brands, Inc. (TLRY)
The 3 Best Cannabis Stocks to Buy in February 2024
3 Risky Penny Stocks That Are Worth the Shot
Tilray Inc (NASDAQ:TLRY) Short Interest Down 9.6% in January
TLRY Feb 2024 3.000 put
See More Headlines
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/10/2023
Today
2/26/2024
Next Earnings (Estimated)
4/08/2024
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:TLRY
Fax
N/A
Employees
1,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.83
High Stock Price Target
$5.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+62.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-1,452,660,000.00
Net Margins
-198.84%
Pretax Margin
-202.20%

Debt

Sales & Book Value

Annual Sales
$627.12 million
Book Value
$5.07 per share

Miscellaneous

Free Float
737,674,000
Market Cap
$1.29 billion
Optionable
Optionable
Beta
2.33
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report














TLRY Stock Analysis - Frequently Asked Questions

Should I buy or sell Tilray stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings
or view top-rated stocks.

What is Tilray's stock price target for 2024?

3 analysts have issued 1 year target prices for Tilray's stock. Their TLRY share price targets range from $2.00 to $5.00. On average, they expect the company's share price to reach $2.83 in the next twelve months. This suggests a possible upside of 62.8% from the stock's current price.
View analysts price targets for TLRY
or view top-rated stocks among Wall Street analysts.

How have TLRY shares performed in 2024?

Tilray's stock was trading at $2.30 on January 1st, 2024. Since then, TLRY stock has decreased by 24.3% and is now trading at $1.74.
View the best growth stocks for 2024 here
.

Are investors shorting Tilray?

Tilray saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 111,880,000 shares, a decrease of 9.6% from the January 15th total of 123,760,000 shares. Based on an average daily trading volume, of 20,430,000 shares, the short-interest ratio is presently 5.5 days.
View Tilray's Short Interest
.

When is Tilray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 8th 2024.
View our TLRY earnings forecast
.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its quarterly earnings data on Monday, April, 10th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $1.84. The company had revenue of $145.59 million for the quarter, compared to the consensus estimate of $150.13 million. Tilray had a negative net margin of 198.84% and a negative trailing twelve-month return on equity of 3.38%. The company's revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the company earned $0.04 EPS.

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an IPO on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Who are Tilray's major shareholders?

Tilray's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.46%), Goldman Sachs Group Inc. (0.00%), Mirae Asset Global Investments Co. Ltd. (0.33%), Point72 Asset Management L.P. (0.32%), Swiss National Bank (0.19%) and TD Asset Management Inc (0.17%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Denise M Faltischek, Irwin D Simon, James R Meiers and Mitchell Gendel.
View institutional ownership trends
.

How do I buy shares of Tilray?

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLRY) was last updated on 2/26/2024 by MarketBeat.com Staff